Automated Cell Counters Market is expected to reach US$ 10,365.95 Million by 2028

Type Segment to Dominate Automated Cell Counters Market

According to The Insight Partners research study, titled "Automated Cell Counters Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type and End User," the market is expected to grow from US$ 6,974.29 million in 2021 to US$ 10,365.95 million by 2028; it is estimated to grow at a CAGR of 5.9% from 2022 to 2028. The rising prevalence of infectious and chronic disease boost the growth of the automated cell counters market. However, a lack of a skilled workforce and the high cost of the instrument are expected to restrict the market growth during the forecast period.

According to World Health Organization (WHO), 41 million people die yearly due to chronic diseases, equivalent to 71% of all deaths globally. As per the Centers for Disease Control and Prevention (CDC), six in ten adults in the US have a chronic disease, and four in ten adults have two or more chronic diseases. According to Cancer Research UK, ~17 million new cases of cancer were detected worldwide in 2018. Further, in 2018, ~9.6 million deaths occurred due to cancer worldwide. Diagnostics are essential in determining the direction of any medical treatment of infectious and chronic diseases. Cell counting is one of the methods that is used for the detection of such diseases. Therefore, the rising prevalence of infectious and chronic diseases across the globe is driving the growth of the automated cell counters market.

Based on type, the automated cell counters market is segmented into spectrophotometers, flow cytometers, hemocytometers, and electrical impedance. The spectrophotometers segment held the largest market share in 2021, and the hemocytometers segment is anticipated to register the highest CAGR during the forecast period. Hemocytometer is the most cost-effective method for cell counting. Hemocytometer is reusable and can be easily used with other common tools in the laboratory, such as an optical microscope. An increase in the incidence of blood cell disorders that cause anemia, thalassemia, lymphoma, leukemia, and other disorders is driving the segment's growth. For instance, according to WHO, in 2019, global anemia prevalence was 29.9%, equivalent to over half a million women aged 15-49 years. Furthermore, in 2019, global anemia prevalence was 39.8% in children aged 6-59 months, equivalent to 269 million children with anemia. A hemocytometer is used for rapid and effective cell count in developing countries to detect anemia.  

Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd; Chemometec A/S; Aligned Genetics; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; Merck KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott Laboratories; and Nexcelom Bioscience LLC are the key companies operating in the automated cell counters market.

Automated Cell Counters Market, by Geography, 2022 (%)

The report segments the Automated Cell Counters market as follows:

The automated cell counters market is segmented into type, end user, and geography. Based on type, the market is segmented into hemocytometers, flow cytometers, electrical impedance, and spectrophotometers. Based on end user, the market is categorized into hospitals, research laboratories, diagnostic centers, and others. By geography, the automated cell counters market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).